## Cholinesterase, α-glucosidase, tyrosinase and urease inhibitory activities of compounds from fruits of *Rinorea oblongifolia* C.H. Wright (Violaceae)

Aristide Mfifen Munvera<sup>a\*</sup>, Alfred Ngenge Tamfu<sup>b,c</sup>, Blandine Marlyse Wache Ouahouo<sup>a</sup>, Selcuk Kucukaydin<sup>c</sup>, Jean Noel Nyemb<sup>d</sup>, Aude Marcelle Fokam Mafo<sup>e</sup>, Emar Carlain Djappa Tchapo<sup>a</sup>, Pierre Mkounga<sup>a</sup>, Augustin Ephrem Nkengfack<sup>a</sup>

<sup>a</sup> Department of Organic Chemistry, Faculty of Science, The University of Yaounde I, Yaounde, 812, Cameroon

<sup>b</sup>Department of Chemical Engineering, School of Chemical Engineering and Mineral Industries, University of Ngaoundere, 454 Ngaoundere, Cameroon

<sup>c</sup>Department of Medical Services and Techniques, Koycegiz Vocational School of Health Services, Mugla Sitki Kocman University, 48800 Mugla, Turkey.

<sup>d</sup>Department of Refining and Petrochemistry, National Advanced School of Mines and Petroleum Industries, University of Maroua, Kaélé, Cameroon

<sup>e</sup>Institute of Medical Research and Medicinal Plants, P.O BOX 13033 Yaoundé-Cameroon \*Corresponding author: <u>mfifena@hotmail.fr</u> (Munvera Mfifen A.)

## Abstract

From *Rinorea oblongifolia* fruits, 3-Nor-4β-friedelan-24-ol (1) and 3-decyl-6,7,8-trimethoxy-2H,5H-furo[4,3,2-de]isochromene-2,5-dione 28-(4), new derivatives alongside. hydroxyfriedelan-3-one (2), friedelin (3), 3,3',4,4',5'-pentamethylcoruleoellagic acid (5), hexamethylcoruleoellagic acid (6), 3',4,4',5,5'-pentamethylcoruleoellagic acid (7), and fatty compounds 8-11 were isolated and characterized using HRESIMS, EIMS, 1D and 2D NMR. In vitro enzyme inhibition of compounds 1, 2, 4, 5, 6 and 7 were evaluated on acetylcholinesterase (AChE), butyrylcholinesterase (BChE), α-glucosidase, urease and tyrosinase. Against AChE and BChE, the phenolic compounds 4, 5, 6, and 7 had good activity probably due to the phenolic nature and methoxy substituents. Compounds 4, 5, 6 and 7 exhibited good  $\alpha$ -glucosidase inhibition especially compound 4 whose IC<sub>50</sub> = 42.45±0.46 µg/ mL was close that of acarbose (IC<sub>50</sub> =  $20.52\pm0.84 \,\mu$ g/mL) standard drug. Urease and tyrosinase were appreciably inhibited by the compounds. Overall results of enzyme inhibitory assays indicate Rinorea oblongifolia, fruits and its constituents as potential remedy for enzymatic disorders.

**Keywords** *Rinorea oblongifolia*, triterpenoids, coruleoellagic acid derivatives, enzyme inhibition, anticholinesterase,  $\alpha$ -glucosidase inhibition

## Supplementary material

Figure S1. HRESI Mass Spectrum of compound 1

Figure S2. IR spectrum of compound 1

**Figure S3.** <sup>13</sup>C NMR spectrum ((CDCl<sub>3</sub>, 200 MHz) of compound **1** 

Figure S4-1. <sup>1</sup>H NMR spectrum (CDCl<sub>3</sub>, 800 MHz) of compound 1

Figure S4-2. <sup>1</sup>H NMR spectrum (CDCl<sub>3</sub>, 800 MHz) of compound 1

Figure S5. DEPT- HSQC spectrum (CDCl<sub>3</sub>, 800 MHz) of compound 1

Figure S6. COSY spectrum (CDCl<sub>3</sub>, 800 MHz) of compound 1

Figure S7-1. HMBC spectrum (CDCl<sub>3</sub>, 800 MHz) of compound 1

Figure S7-2. HMBC spectrum (CDCl<sub>3</sub>, 800 MHz) of compound 1

Figure S7-3. HMBC spectrum (CDCl<sub>3</sub>, 800 MHz) of compound 1

Figure S8-1. NOESY spectrum (CDCl<sub>3</sub>, 800 MHz) of compound 1

Figure S8-2. NOESY spectrum (CDCl<sub>3</sub>, 800 MHz) of compound 1

Figure S9. HMBC and NOESY correlation of compound  ${\bf 1}$ 

Figure S10-1. HR ESI Mass Spectrum of compound 4

Figure S10-2. LR EI Mass spectrum of compound 4

Figure S11. IR spectrum of compound 4

Figure S12. UV spectrum of compound 4

Figure S13-1. <sup>1</sup>H NMR spectrum (CDCl<sub>3</sub>, 500 MHz) of compound of compound 4

Figure S13-2. <sup>1</sup>H NMR spectrum (CDCl<sub>3</sub>, 500 MHz) of compound of compound 4

Figure S14. <sup>13</sup>C NMR spectrum (CDCl<sub>3</sub>, 125 MHz) of compound 4

Figure S15. DEPT spectrum (CDCl<sub>3</sub>, 125 MHz) of compound 4

Figure S16. DEPT- HSQC spectrum (CDCl<sub>3</sub>, 500 MHz) of compound 4

Figure S17. HMBC spectrum (CDCl<sub>3</sub>, 500 MHz) of compound 4

Figure S18. NOESY spectrum (CDCl<sub>3</sub>, 500 MHz) of compound 4

Figure S19. HMBC and NOESY correlation of compound 4

**Table S1.** The NMR spectral data of compound 1

Table S2. The NMR spectral data of compound 4

**Table S3.** Cholinesterase,  $\alpha$ -glucosidase, urease and tyrosinase inhibitory activities of the isolated compounds



Figure S1: HRESI Mass Spectrum of compound 1



Figure S2: IR spectrum of compound 1





Figure S3: <sup>13</sup>C NMR spectrum ((CDCl<sub>3</sub>, 200 MHz) of compound 1







Figure S5: DEPT- HSQC spectrum (CDCl<sub>3</sub>, 800 MHz) of compound 1



Figure S6: COSY spectrum (CDCl<sub>3</sub>, 800 MHz) of compound 1



Figure S7-1: HMBC spectrum (CDCl<sub>3</sub>, 800 MHz) of compound 1



Figure S7-2: HMBC spectrum (CDCl<sub>3</sub>, 800 MHz) of compound 1



Figure S7-3: HMBC spectrum (CDCl<sub>3</sub>, 800 MHz) of compound 1







Figure S8-2: NOESY spectrum (CDCl<sub>3</sub>, 800 MHz) of compound 1



Figure S9: HMBC and NOESY correlation of compound 1



Figure S10-1: HR ESI Mass Spectrum of compound 4



Figure S10-2: LREI Mass Spectrum of compound 4



Figure S11: IR spectrum of compound 4 Scan Graph



Figure S12: UV spectrum of compound 4



Figure S13-1: <sup>1</sup>H NMR spectrum (CDCl<sub>3</sub>, 500 MHz) of compound of compound 4



Figure S13-2: <sup>1</sup>H NMR spectrum (CDCl<sub>3</sub>, 500 MHz) of compound of compound 4

BB

<107.89-163.06 -161.46 -154.13 -152.83 -149.95 -114.2149.17 49.00 48.82 48.66 48.49 34.88 63.30 51 19.34 -163. 6 Т 180 160 120 60 100 140 80 40 20 ppm

Figure S14: <sup>13</sup>C NMR spectrum (CDCl<sub>3</sub>, 125 MHz) of compound 4



Figure S15: DEPT spectrum (CDCl<sub>3</sub>, 125 MHz) of compound 4 Dept-HSQC



Figure S16: DEPT- HSQC spectrum (CDCl<sub>3</sub>, 500 MHz) of compound 4



Figure S17-1: HMBC spectrum (CDCl<sub>3</sub>, 500 MHz) of compound 4 HMBc



Figure S17-2: HMBC spectrum (CDCl<sub>3</sub>, 500 MHz) of compound 4



Figure S18: NOESY spectrum (CHCl<sub>3</sub>, 500 MHz) of compound 4



Figure S19: HMBC and NOESY correlation of compound 1

position	δc (ppm)	δH (ppm)
1	20.0	
2	39.1	
3	-	
4	53.0	1,22 ; m
5	50.7	
6	35.2	
7	19.2	
8	52.6	1,47 ; m
9	37,6	
10	57.0	1, 18 ; m
11	35.9	
12	30.1	
13	39.2	
14	38.1	
15	32.8	
16	36.6	
17	30.1	
18	42.7	1.48; m
19	34.8	
20	28.1	
21	34.1	
22	39.5	
23	8.6	0.93 (3H, d, 7.5 Hz)
24	72.8	3.55 ; H24a ; d, <i>J</i> = 8.5 Hz
25	164	4.11; H24b; d, $J=8.5$ Hz
25	16.4	0.92 (3H, s)
26	20.4	0.95 (3H, s)
27	18.6	0.98 (3H, s)
28	32.1	0.96 (3H, s)
29	35.2	0.91 (3H, s)
30	31.8	1.13 (3H, s)

 Table S1: The NMR spectral data of compound 1

position	δH (ppm)	δc (ppm)
1	-	-
2		175.2
2a	-	114.2
3	-	161.5
4	-	-
5	-	163.1
5a		107.5
6		154.1
7		148.1
8		150.0
8a		152.8
8b		107.9
1'	2.39	35.8
2'	1.60	26.1
3'-9'	1.23-1.26	23.6-34.8
10'	0.86	14.5
6-OCH <sub>3</sub>	3.99	62.7
7- OCH3	4.23	62.4
8- OCH <sub>3</sub>	4.01	62.5

 Table S2. The NMR spectral data of compound 2

	Cholinesterase inhibitory activity									
	AChE inhibition		BChE inhibition		α-glucosidase inhibition		Urease inhibition		Tyrosinase inhibition	
Test samples	Inh. (%) (at 100 µg/mL)	IC50 (µg/mL)	Inhibition (%) (at 100 µg/mL)	IC <sub>50</sub> (µg/mL)	Inh. (%) (at 100 µg/mL)	IC <sub>50</sub> (µg/mL)	Inh. (%) (at 100 µg/mL)	IC <sub>50</sub> (µg/mL)	Inh. (%) (at 100 μg/mL)	IC <sub>50</sub> (μg/mL)
1	28.00±0.74	>100	46.61±0.33	>100	46.15±0.22	>100	51.83±0.66	96.43±0.75	46.98±0.34	>100
2	24.00±0.22	>100	33.40±0.63	>100	43.56±0.45	>100	52.27±0.70	94.85±0.76	25.51±0.33	>100
4	48.72±0.45	>100	60.47±1.25	70.87±0.95	73.91±1.20	42.45±0.46	58.63±0.44	75.17±0.63	35.21±0.46	>100
5	35.90±0.26	>100	57.43±0.53	76.41±0.79	66.30±0.62	60.51±0.67	58.33±0.25	75.48±0.58	75.90±0.85	36.24±0.86
6	37.30±0.16	>100	59.62±0.77	71.24±0.56	64.78±1.10	68.79±1.25	61.20±0.56	66.45±0.38	76.51±0.77	35.72±0.55
7	32.63±0.54	>100	50.42±0.21	98.86±0.90	65.39±1.05	66.80±1.30	46.30±0.20	>100	55.25±0.80	81.34±0.48
Galantamine	85.50±0.70	5.50±0.25	74.65±0.20	42.10±0.45	NT	NT	NT	NT	NT	NT
Thiourea	NT	NT	NT	NT	NT	NT	83.75±0.60	8.20±0.35	NT	NT
Kojic acid	NT	NT	NT	NT	NT	NT	NT	NT	79.50±0.32	23.75±0.20
Acarbose	NT	NT	NT	NT	82.40±0.70	20.52±0.84	NT	NT	NT	NT

**Table S3.** Cholinesterase,  $\alpha$ -glucosidase, urease and tyrosinase inhibitory activities of the isolated compounds

Values represent the means  $\pm$  SEM of three parallel sample measurements (p < 0.05). *NT*: not tested.